Mutations associated with virological response to darunavir/ritonavir in HIV-1-infected protease inhibitor-experienced patients

The Journal of Antimicrobial Chemotherapy
Diane DescampsFrançoise Brun-Vézinet

Abstract

The aim of the study was to identify a pattern of protease gene mutations associated with the virological response to darunavir/ritonavir-based regimens. We analysed 153 treatment-experienced patients receiving a darunavir/ritonavir salvage regimen as a sole protease inhibitor (PI). Virological response was defined as an HIV-1 RNA load of <200 copies/mL at month 3. The impact of individual protease gene mutations on the virological response to darunavir/ritonavir was examined, and the combination of mutations most strongly associated with the virological response was identified. The baseline median HIV RNA level was 4.7 log(10) copies/mL and the median CD4 cell count was 142 cells/mm(3). At month 3, 55% of patients had a virological response and the median fall in viral load from baseline was 1.7 log(10) copies/mL. All the patients had detectable darunavir concentrations at month 3. Cochran-Armitage procedure identified eight mutations with a negative impact on the virological response, namely K14R, K20I, E34Q, I47V, I54M, K55R, T74P and I84V; and two mutations (E35D and V82A) with a positive impact. In multivariate analyses, our genotypic scores were highly predictive of the virological response at month 3, along with the base...Continue Reading

References

Aug 2, 2003·AIDS·Françoise Brun-VézinetUNKNOWN Narval (ANRS 088) Study group
Mar 18, 2005·Journal of Medicinal Chemistry·Dominique L N G SurlerauxPiet B T P Wigerinck
Apr 28, 2005·Antimicrobial Agents and Chemotherapy·Anne-Geneviève MarcelinUNKNOWN AI454-176 Jaguar Study Team
Dec 24, 2005·Journal of Medical Virology·Diane DescampsDominique Costagliola
Apr 7, 2007·AIDS·Richard HaubrichUNKNOWN POWER 2 Study Group
Jan 30, 2008·Antimicrobial Agents and Chemotherapy·Delphine DesboisUNKNOWN French ANRS HIV-2 Cohort (ANRS CO 05 VIH-2)
Mar 11, 2008·AIDS Research and Human Retroviruses·Sandra de MeyerMarie-Pierre de Béthune
Jul 16, 2008·Antimicrobial Agents and Chemotherapy·Anne-Genevieve MarcelinVincent Calvez
Jul 25, 2008·The New England Journal of Medicine·Roy T SteigbigelUNKNOWN BENCHMRK Study Teams
Aug 5, 2008·JAMA : the Journal of the American Medical Association·Scott M HammerUNKNOWN International AIDS Society-USA

❮ Previous
Next ❯

Citations

Jun 27, 2012·The Journal of Antimicrobial Chemotherapy·Sidonie Lambert-NiclotUNKNOWN EOLE Study Group
Feb 2, 2011·Antimicrobial Agents and Chemotherapy·Lucile LarrouyDiane Descamps
Nov 11, 2009·Antimicrobial Agents and Chemotherapy·Anne-Genevieve MarcelinUNKNOWN ANRS AC11 Resistance Study Group
Jan 31, 2016·The Journal of Antimicrobial Chemotherapy·Andrea De LucaUNKNOWN CHAIN and COHERE in EuroCoord
Jan 26, 2010·Journal of Clinical Virology : the Official Publication of the Pan American Society for Clinical Virology·C DelaugerreP de Truchis
Nov 10, 2011·Journal of Acquired Immune Deficiency Syndromes : JAIDS·Gaetana SterrantinoUNKNOWN ARCA Database Study Group
Feb 13, 2009·The Journal of Infectious Diseases·Birgitte B SimenUNKNOWN Terry Beirn Community Programs for Clinical Research on AIDS
Dec 14, 2019·Journal of Biomolecular Structure & Dynamics·Dhoha TrikiLeslie Regad
Jan 19, 2016·The Pediatric Infectious Disease Journal·Tiffeny T SmithAllison L Agwu
Jul 8, 2011·Journal of Acquired Immune Deficiency Syndromes : JAIDS·Charlotte CharpentierDiane Descamps

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antimicrobial Resistance (ASM)

Antimicrobial resistance poses a significant threat to the continued successful use of antimicrobial agents for the treatment of bacterial infections.

Antimicrobial Resistance

Antimicrobial resistance poses a significant threat to the continued successful use of antimicrobial agents for the treatment of bacterial infections.